NFIB and adrenal cortex carcinoma: The combination of anlotinib with the tubulin binder eribulin showed an enduring response in a MYB-NFIB and BCOR (BCL6 corepressor) mutant ACC patient after chemotherapy (carboplatin, cyclophosphamide, doxorubicin) had failed[158].